Biocartis to Present Idylla™ Breast21 Assay Data at SABCS 2026
News related to:Biocartis NV · 2 min read
PRESS RELEASE, October 30, 2026 /CourierPR/ -- Biocartis, an innovative molecular diagnostics company, is set to present initial development data for its Idylla™ Breast21 Assay at the San Antonio Breast Cancer Symposium (SABCS) 2026. The company announced that an abstract on the Idylla™ Breast21 Assay will be accepted for a poster presentation at the event, which is scheduled for December 8-11, 2026, in San Antonio, Texas, US.
This includes training and testing data, which will be detailed in the presentation.
The established 21-gene Recurrence Score is a widely validated genomic signature that provides prognostic and predictive information in hormone receptor-positive, HER2-negative early-stage breast cancer. However, testing currently relies on centralized laboratory services, which can add time to the treatment decision-making process and may limit access to testing in some settings. The Idylla™ Breast21 Assay is being developed as an ultra-rapid, fully automated, and decentralized alternative that measures RNA expression of the same 21 genes from formalin-fixed paraffin-embedded (FFPE) tissue to deliver a recurrence-risk score.
Initial development data show strong risk class agreement between the Idylla™ Breast21 Prototype Assay and the reference method.
Biocartis is committed to helping cancer patients worldwide access the right treatment faster. With its proprietary Idylla™ System, the company delivers in-house molecular biomarker results in only 3 hours, enabling healthcare professionals to make timely, informed decisions that guide personalized therapy. The expanding portfolio of diagnostic tests and research assays addresses key unmet clinical needs across multiple cancers, including lung, skin, thyroid, colorectal, endometrial, blood, brain, and breast cancer.
The Idylla™ System is CE-marked in Europe in compliance with EU IVD Regulation 2017/746, listed as a class II device in the US under establishment registration 3009972873, and registered in many other countries.
The poster presentation at SABCS 2026 will provide a platform for Biocartis to showcase the potential of the Idylla™ Breast21 Assay in transforming the way recurrence risk is assessed in early-stage breast cancer. The company's commitment to innovation and patient care is evident in the development of this ultra-rapid, fully automated assay that could significantly improve the speed and accessibility of genomic testing.
The San Antonio Breast Cancer Symposium (SABCS) is a leading international forum for the exchange of the latest research and clinical advances in breast cancer. The event attracts a diverse group of attendees, including clinicians, researchers, and industry leaders, who will have the opportunity to learn about the advancements in breast cancer diagnostics and treatment strategies.
Biocartis's participation in SABCS 2026 underscores its dedication to advancing the field of molecular diagnostics and improving patient outcomes. The company's work on the Idylla™ Breast21 Assay represents a significant step towards making reliable genomic recurrence-risk testing more accessible and efficient for healthcare providers and patients alike.